Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Telomerase inhibitors available for licensing from CRCT

May 11, 1999

Antioxidant di- and triacetic acid derivatives: preparation and use described by L'Oreal

May 11, 1999

Structural Bioinformatics develops antagonists of BcL-2 gene product

May 10, 1999

Licensing opportunity from NIH: recombinant antitumor RNases

May 10, 1999

BE-55051: novel antitumor substance produced by Streptomyces

May 7, 1999

Second-generation SERM advances through the Lilly pipeline

May 7, 1999

Clinical trials of SuperGen's RFS-2000 expanded to Europe

May 7, 1999

NCI funds phase II trials of Sugen's lead angiogenesis inhibitor

May 7, 1999

New phase I/II study evaluates G-3139 + docetaxel

May 6, 1999

New Incyte invention provides RBTNH and related products, and use thereof

May 6, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...